1 |
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-659.
DOI
ScienceOn
|
2 |
Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
DOI
ScienceOn
|
3 |
Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6: 1370-1377.
DOI
ScienceOn
|
4 |
Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114: 1133-1142.
DOI
ScienceOn
|
5 |
Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-1346.
DOI
ScienceOn
|
6 |
Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-36.
DOI
ScienceOn
|
7 |
Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-759.
DOI
ScienceOn
|
8 |
Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.
DOI
ScienceOn
|
9 |
Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16:399-406.
DOI
ScienceOn
|
10 |
Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101:793-797.
DOI
ScienceOn
|
11 |
Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol 2009;9:22.
DOI
ScienceOn
|
12 |
Kim KO, Jang BI. Emerging drugs in the treatment of inflammatory bowel disease: beyond anti-TNF-. Korean J Gastroenterol 2011;58:235-244.
DOI
ScienceOn
|
13 |
Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-678.
DOI
ScienceOn
|
14 |
Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-1897.
DOI
ScienceOn
|
15 |
Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
DOI
ScienceOn
|
16 |
Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003;68:63-70.
DOI
ScienceOn
|
17 |
Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360:1478-1480.
DOI
ScienceOn
|
18 |
Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-1144.
|
19 |
Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137.
|
20 |
Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-242.
DOI
ScienceOn
|
21 |
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION Study. Ann Rheum Dis 2010;69:88-96.
DOI
ScienceOn
|
22 |
Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-232.
DOI
|
23 |
Berg DJ, Davidson N, Kühn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-1020.
DOI
ScienceOn
|
24 |
Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group. Gastroenterology 1997; 113:383-389.
DOI
ScienceOn
|
25 |
Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease: the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-1482.
DOI
ScienceOn
|
26 |
Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease: Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-1472.
DOI
ScienceOn
|
27 |
Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-46.
DOI
ScienceOn
|
28 |
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
DOI
ScienceOn
|
29 |
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885.
DOI
ScienceOn
|
30 |
Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-450.e1.
DOI
ScienceOn
|
31 |
D'haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European Multicenter Trial. Gastroenterology 1999;116:1029-1034.
DOI
ScienceOn
|
32 |
Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM Study. Gastroenterology 2008;135:1493-1499.
DOI
ScienceOn
|
33 |
Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-932.
DOI
ScienceOn
|
34 |
Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. 2006;12:9-15.
DOI
ScienceOn
|
35 |
Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852.
DOI
ScienceOn
|
36 |
MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140:1768-1775.
DOI
ScienceOn
|
37 |
Semerano L, Assier E, Delavallée L, Boissier MC. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011;11:545-550.
DOI
ScienceOn
|
38 |
Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. 2008;135:1130-1141.
|
39 |
Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351: 2069-2079.
DOI
ScienceOn
|
40 |
Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008;103:3167-3182.
DOI
ScienceOn
|
41 |
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
DOI
ScienceOn
|
42 |
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-583.
DOI
|
43 |
Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998;4:328-329.
DOI
|
44 |
Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010;24(Suppl 1):3-14.
DOI
ScienceOn
|
45 |
Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-1181.
DOI
ScienceOn
|
46 |
Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782.
DOI
ScienceOn
|
47 |
Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250.
DOI
ScienceOn
|
48 |
Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease: experience with 1379 patients. Ann Surg 1991;214:230-238.
DOI
ScienceOn
|
49 |
Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-592.
DOI
|
50 |
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678.
DOI
ScienceOn
|
51 |
Shanahan WR Jr. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert opin Investig Drugs 1999;8:1417-1429.
DOI
ScienceOn
|
52 |
Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005;21: 391-400.
DOI
ScienceOn
|
53 |
Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID Study. Inflamm Bowel Dis 2008;14:542-549.
DOI
ScienceOn
|
54 |
Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-879.
DOI
ScienceOn
|
55 |
Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895-902.
DOI
ScienceOn
|
56 |
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in populationbased cohorts. Am J Gastroenterol 2010;105:289-297.
DOI
ScienceOn
|
57 |
Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-2201.
DOI
ScienceOn
|
58 |
Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid- dependent Crohn's disease: a randomised, double-blind, placebo- controlled, phase 2 study. Gut 2009;58:1354-1362.
DOI
ScienceOn
|
59 |
Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010;16:1203-1208.
DOI
ScienceOn
|
60 |
Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo- controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274.
DOI
ScienceOn
|
61 |
Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-1683.
DOI
ScienceOn
|
62 |
Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996.
DOI
ScienceOn
|